SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5
Rhea-AI Summary
SINTX Technologies (NASDAQ: SINT) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on February 4–5, 2026, with its presentation on Wednesday, February 4, 2026 at 12:00 p.m. ET.
The webcast will be available via the company’s investor site. Management will provide updates on operational progress, strategic priorities, its silicon nitride biomaterial platform, recent regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications.
Positive
- None.
Negative
- None.
News Market Reaction – SINT
In the Jan 29 session, SINT declined 2.41%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Investor conference | Positive | +4.5% | Announcement of participation in Sidoti virtual investor conference with webcast access. |
| Dec 01 | Supply agreement | Positive | -21.2% | Supply deal with Evonik for SiN/PEEK compound for AI-assisted 3D-printed implants. |
| Nov 13 | Earnings & update | Positive | -10.8% | Q3 2025 update highlighting FDA clearance, first revenues, capital raised, and cost savings. |
| Nov 03 | Product launch | Positive | +4.7% | Launch of OsseoSculpt biologic complementing cleared SINAPTIC Foot & Ankle system. |
| Oct 20 | FDA clearance | Positive | -15.4% | FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System enabling U.S. entry. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several positive operational or regulatory updates with mixed to negative next-day price reactions, indicating a tendency toward selling or muted responses even on upbeat news.
Over the past few months, SINTX announced multiple milestones, including FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System, launch of the OsseoSculpt™ biologic, and a supply agreement for its SiN/PEEK compound. It also regularly participates in investor conferences, such as Sidoti’s event on Dec 10–11, 2025. Today’s Noble conference announcement continues this pattern of outreach and platform-building communications following operational restructuring.
Key Terms
silicon nitride medical
biomaterial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026.
The Company’s participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and several strategic initiatives underway, SINTX believes the Noble Conference provides a constructive forum to engage with institutional investors seeking differentiated medtech opportunities.
Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Dates: February 4–5, 2026
- Presentation Date & Time: Wednesday, February 4, 2026, at 12:00 p.m. ET
- Webcast: https://investors.sintx.com/news-events/events-presentations
During the conference, SINTX management will provide an update on the Company’s operational progress and strategic priorities, including its expanding silicon nitride biomaterial platform, recent regulatory milestones, and opportunities for value creation in orthopedic, spine, and patient-specific applications.
Noble’s Emerging Growth Conference is widely followed by institutional investors, family offices, and research analysts focused on fundamentally driven, under-followed growth companies, and SINTX looks forward to participating in one-on-one meetings and investor discussions throughout the event.
To schedule a one-on-one meeting with SINTX Technologies’ management team, please contact KCSA Strategic Communications at Sintx@kcsa.com.
To be added to the SINTX Technologies email distribution list, please email Sintx@kcsa.com with “SINT” in the subject line.
About SINTX Technologies, Inc.
Based in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is a pioneer in advanced ceramics specializing in silicon nitride-based materials for medical and other high-value applications. SINTX’s biomaterials have been implanted in humans since 2008, and the company continues to expand its portfolio of next-generation orthopedic, spine, and patient-specific solutions through strategic innovation and partnerships.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties, and actual results may differ materially from those described.
SINTX Contacts:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
Sintx@kcsa.com
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
